Melatonin Agb (Melatonin)

• Melatonin Agb is used to address sleep disorders by modulating the melatonin signaling pathway.
• Insomnia: helps reduce sleep onset latency and improve total sleep time in individuals with difficulty falling asleep.
• Delayed sleep phase disorder: advances the timing of the circadian rhythm to align sleep periods with desired schedules.
• Shift work disorder: assists workers with irregular schedules to achieve better sleep alignment during daytime sleep periods.

• Melatonin Agb contains melatonin, which binds to MT1 and MT2 receptors located in the suprachiasmatic nucleus of the hypothalamus. Activation of MT1 reduces neuronal firing during the night, while MT2 phase‑shifts circadian rhythms. Together these actions synchronize the internal clock with the external light‑dark cycle, promoting sleep initiation and maintenance. The resulting increase in endogenous melatonin signaling supports the natural decline in alertness and facilitates the transition to sleep.

Melatonin Agb may be associated with several adverse reactions, ranging from mild to rare serious events.

Common Side Effects

• Headache: mild headache reported in some users.
• Dizziness: transient light‑headedness.
• Daytime sleepiness: residual drowsiness after dosing.
• Nausea: mild gastrointestinal upset.
• Vivid dreams: unusual dream patterns.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, swelling, or anaphylaxis.
• Mood changes: worsening depression or suicidal thoughts.
• Cardiac effects: rare cases of arrhythmia or palpitations.
• Hormonal effects: potential impact on reproductive hormones in long‑term use.

• When considering Melatonin Agb, several safety measures should be observed.
• Assess underlying conditions: evaluate for sleep apnea or other sleep‑related disorders before initiating therapy.
• Avoid in children without supervision: pediatric use should be guided by a qualified healthcare professional.
• Monitor for depression: watch for mood changes, especially in patients with a history of depression.
• Consider drug interactions: review concomitant medications that may affect melatonin metabolism.
• Do not operate machinery if drowsy: ensure adequate alertness before engaging in tasks requiring concentration.
• Store at ambient temperature: keep in the original pack, protect from moisture and light.

Melatonin Agb can interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid)

• Anticoagulants: may increase bleeding risk.
• Immunosuppressants: may reduce their efficacy.
• CYP1A2 inhibitors: can raise melatonin plasma concentrations.

Moderate Interactions (Monitor Closely)

• CNS depressants: additive sedation may occur.
• Caffeine: may diminish melatonin's sleep‑promoting effect.
• Oral contraceptives: can increase melatonin levels, requiring monitoring.